Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.
Our mission at Altimmune is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.
Altimmune, Inc. (formerly known as Vaxin Inc.) was founded in 1997 to discover and develop novel products that engage, stimulate and improve immune responses for the prevention and treatment of disease. The recent acquisition of Immune Targeting Systems (ITS), Limited has consolidated our immunotherapeutic product pipeline and expertise while creating a global presence.